EUCTR2017-000800-59-DE进行中（未招募）1 期
A Phase 1 /2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) - LIBRETTO-001
oxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company0 个研究点目标入组 995 人开始时间: 2018年8月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 995
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with a locally advanced or metastatic solid tumor who:
- •-have progressed on or are intolerant to standard therapy, or
- •-no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or
- •-decline standard therapy.
- •2. Prior multi-kinase inhibitors (MKIs) with anti-RET activity are allowed.
- •3. A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and /or blood is required
- •4. Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type.
- •5. At least 18 years of age.
- •-Enrollment of minors are not allowed in Germany.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (age = 16 years) or Lansky Performance Score (LPS) = 40% (age < 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment.
- •7. Life expectancy of at least 3 months.
- •8. Archived tumor tissue sample available
- •9. Adequate hematologic status, defined as:
- •Absolute neutrophil count (ANC) = 1.0 × 109/L not requiring growth factor support for at least 7 days prior to treatment, and
- •Platelet count = 75 × 109/L not requiring transfusion support for at least 7 days prior to treatment, and
- •Hb = 9 g/dL not requiring transfusion support or erythropoietin for at least 7 days prior to treatment.
- •10. Adequate hepatic function, defined as:
- •ALT and AST = 2.5 × the upper limit of normal (ULN) or = 5 × ULN with documented liver involvement (such as liver metastasis or a primary biliary tumor); and
- •Total bilirubin = 1.5 × ULN or = 3 × ULN with documented liver involvement (patients with Gilbert’s Disease may be enrolled with prior Sponsor approval).
- •11. Adequate renal function, with estimated glomerular filtration rate = 30 mL/minute.
- •12. Ability to swallow capsules and comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation. If the liquid formulation is widely available the requirement may be waived with Sponsor approval.
- •13. Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 1 month following the last dose of study treatment;
- •14. Only adult patients capable of understanding the nature, significance and consequences of the clinical trial and providing informed consent are eligible for participation in the planned clinical trial.
- •As for phase 1 with the following modifications:
- •1. Cohorts 1 and 3: failed or intolerant to standard of care; Cohorts 2 and 4: without prior standard first-line therapy; see Table 3 for examples.
- •2. Cohorts 1-4: enrollment will be restricted to patients with evidence of a RET gene alteration in tumor (i.e., not just blood) as defined in Table 3-3. However, a positive germline DNA test for a RET gene mutation as defined in Table 3-3 is acceptable in the absence of tumor tissue testing for patients with MTC.
- •3. Cohorts 1-4: at least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated (unless PD for the irradiated lesion[s] has been radiographically documented).
- •4. Cohort 4: radiographic PD within the previous 14 months.
- •5. Cohort 6: Patients who otherwise are eligible for Cohorts 1-5 who discontinued another RET inhi
排除标准
- •1. Phase 2 Cohorts 1-4: an additional validated oncogenic driver that could cause resistance to LOXO-292 treatment. See Appendix C (Table 11-3) for examples.
- •2. Phase 2 Cohorts 1-5: prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]).
- •Patients otherwise eligible for Cohorts 1-5 who discontinue another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval.
- •3. Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives prior to planned start of selpercatinib, with the exception of immune checkpoint inhibitors (ICI) therapy which shall not be administered within 4 weeks prior to planned start of selpercatinib. In addition, no concurrent investigational anti-cancer therapy is permitted.
- •4. Major surgery (excluding placement of vascular access) within 4 weeks prior to planned start of selpercatinib.
- •5. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study
- •6. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
- •7. Symptomatic primary central nervous system (CNS) tumor, metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression.
- •Patients are eligible if neurological symptoms and CNS imaging are stable and steroid dose is stable for 14 days prior to the first dose of LOXO-292 and no CNS surgery or radiation has been performed for 28 days, 14 days if stereotactic radiosurgery (SRS).
- •8. Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of selpercatinib or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec during Screening. Correction of suspected drug-induced QTcF prolongation may be attempted at the Investigator’s discretion if clinically safe to do so.
- •9. Active uncontrolled systemic bacterial, viral, or fungal infection, or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
- •10. Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
- •11.Uncontrolled symptomatic hyperthyroidism or hypothyroidism.
- •12.Uncontrolled symptomatic hypercalcemia or hypocalcemia.
- •13. Pregnancy or lactation.
- •14. Active second malignancy other than minor treatment of indolent cancers.
- •15. History of hypersensitivity to any of the study drug capsule components, or any of the liquid suspension components (for patients that cannot swallow capsules).
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 study on the effects of Selpercatinib (LOXO-292) (study drug) in patients with advanced solid tumorsEUCTR2017-000800-59-DKoxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company995
进行中（未招募）
1 期
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors.CTIS2023-507702-13-00oxo Oncology Inc.857
进行中（未招募）
1 期
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Medullary Thyroid CancerColon CancerAny Solid TumorNon-Small Cell Lung CancerNCT03157128Eli Lilly and Company857
进行中（未招募）
2 期
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationSolid TumorMedullary Thyroid CancerNCT04280081Eli Lilly and Company77
招募中
2 期
Phase II Study of Selpercatinib in Patients with Advanced Non-Small-Cell Lung Carcinoma harboring RET Rearrangement detected by Liquid Biopsyon-small cell lung cancer with RET fusion positive by Liquid NGS analysisJPRN-jRCT2031210005osaki Kaname21